Cancer-Focused Biotech Aeglea Sets Terms On $60M IPO

By Tom Zanki
March 29, 2016, 5:02 PM EDT

Venture-backed Aeglea BioTherapeutics Inc., a pre-revenue biotech developing treatments for genetic metabolic diseases and cancer, set terms Monday for a $60 million initial public offering, marking rare progress in an IPO...

Already a subscriber? Click here to view full article